Anderson RyanSenior Group Leader in Radiation Oncology University of Oxford
Manuel HidalgoVice Director of Translational Research Spanish National Cancer Research Centre (CIOCC)
Barry DaviesPrincipal Scientist AstraZeneca
Sabine HovesSenior Scientist, Discovery Oncology Roche
Following what was a fantastic couple of days in Boston for the Tumor Model community, we are pleased to show you what's in store for the 4th Tumour Models Summit, London!
The number one aim of this year's Tumour Model London meeting is to improve the predictability and translatability of preclinical oncology research
This is the must attend meeting for preclinical oncologists, translational scientists and tumour model developers who are constantly striving to improve the predictive ability of basic oncology research and the translational success of their candidates.
With an in-depth focus on cutting edge in vivo and in vitro modelling best practice, you will discover how the movement towards more physiologically relevant models will better mimic the tumour environment, better represent the patient population and help you prioritise the best drug candidates.
Gain access to exclusive unpublished case study data, excellent networking sessions with senior level executives and industry-defining information on effective preclinical strategies that will improve the data interpretation from your tumour model studies and reduce failure rates of oncology clinical trials.
Here’s a quick snapshot of what you’ll get from attending Tumour Models London:
So what can you do to get involved?
“I thought the meeting had exceeded my expectations and found it an excellent forum to open discuss the utility and challenges of our current tumor models.” Deepak Sampath, Senior Scientist, Translational Oncology, Genentech